Hudson Bay Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.41M | Sell |
258,681
-121,519
| -32% | -$4.42M | 0.03% | 262 |
|
|
2025
Q1 | $13.8M | Buy |
380,200
+2,700
| +0.7% | +$97.8K | 0.04% | 195 |
|
|
2024
Q4 | $15.9M | Buy |
377,500
+182,500
| +94% | +$7.68M | 0.06% | 172 |
|
|
2024
Q3 | $10.8M | Sell |
195,000
-220,000
| -53% | -$12.2M | 0.04% | 180 |
|
|
2024
Q2 | $17.1M | Buy |
415,000
+109,900
| +36% | +$4.52M | 0.08% | 101 |
|
|
2024
Q1 | $14.2M | Sell |
305,100
-184,900
| -38% | -$8.63M | 0.08% | 105 |
|
|
2023
Q4 | $23.4M | Sell |
490,000
-244,272
| -33% | -$11.7M | 0.15% | 71 |
|
|
2023
Q3 | $26.2M | Buy |
734,272
+232,500
| +46% | +$8.29M | 0.21% | 59 |
|
|
2023
Q2 | $23.1M | Sell |
501,772
-70,000
| -12% | -$3.23M | 0.17% | 75 |
|
|
2023
Q1 | $22.9M | Buy |
571,772
+5,772
| +1% | +$231K | 0.19% | 66 |
|
|
2022
Q4 | $26.2M | Buy |
566,000
+226,000
| +66% | +$10.5M | 0.27% | 66 |
|
|
2022
Q3 | $14.1M | Buy |
340,000
+249,000
| +274% | +$10.3M | 0.12% | 91 |
|
|
2022
Q2 | $5.43M | Buy |
+91,000
| New | +$5.43M | 0.04% | 361 |
|
|
2020
Q4 | – | Sell |
-30,000
| Closed | -$2.47M | – | 669 |
|
|
2020
Q3 | $2.47M | Sell |
30,000
-105,000
| -78% | -$8.63M | 0.04% | 319 |
|
|
2020
Q2 | $10.6M | Sell |
135,000
-98,706
| -42% | -$7.72M | 0.18% | 87 |
|
|
2020
Q1 | $10.4M | Sell |
233,706
-56,294
| -19% | -$2.5M | 0.26% | 66 |
|
|
2019
Q4 | $12.4M | Buy |
290,000
+135,000
| +87% | +$5.77M | 0.28% | 60 |
|
|
2019
Q3 | $6.63M | Buy |
155,000
+45,000
| +41% | +$1.93M | 0.18% | 106 |
|
|
2019
Q2 | $6.99M | Hold |
110,000
| – | – | 0.16% | 117 |
|
|
2019
Q1 | $7.63M | Buy |
110,000
+10,000
| +10% | +$694K | 0.1% | 104 |
|
|
2018
Q4 | $4.35M | Buy |
+100,000
| New | +$4.35M | 0.06% | 183 |
|
|
2018
Q2 | – | Sell |
-120,000
| Closed | -$6.12M | – | 599 |
|
|
2018
Q1 | $6.12M | Buy |
120,000
+20,000
| +20% | +$1.02M | 0.13% | 98 |
|
|
2017
Q4 | $4.64M | Buy |
+100,000
| New | +$4.64M | 0.1% | 122 |
|